Tuesday, November 24, 2020 12:24:20 PM
Organicell Announces Additional Site for Phase I/II Clinical Trial of ZofinTM for treatment of COVID-19
Miami, FL (November 18, 2020) - Organicell Regenerative Medicine, Inc. (OTCBB: BPSR), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, announced today that it is now enrolling patients at an additional site, Larkin Hospital North located in Hialeah, Florida for its Phase I/I clinical trial for the use of its Zofin™ therapeutic in treatment of COVID-19.
This multi-center, randomized, double-blinded, placebo-controlled phase I/II clinical trial is being conducted to investigate the safety and potential efficacy of intravenous infusion of Zofin™ for the treatment of moderate to severe acute respiratory syndrome (SARS) related to COVID-19. The study will be enrolling 20 participants. As of November 17, 2020, several patients have already begun treatment at Larkin Hospital South, located in South Miami, Florida.
“The addition of this clinical trial site is another step towards determining whether to apply for FDA approval for the use of Zofin™ as a COVID-19 treatment, and increases our capacity for participating patients in order to finalize this clinical trial by year’s end,” said Albert Mitrani, Chief Executive Officer of Organicell.
“To date, we have successfully enrolled several patients who have begun treatment in this trial, with no reported serious adverse events. We are looking forward to continued progress as we enroll additional patients in the coming weeks. Most of all, we are eager to begin enrollment at Larkin Community Hospital North this week,” said Dr. Luis Mendez-Mulet, Infectious Disease Specialist at Alternative Research Associates and Larkin Community Hospital.
“We are excited to sign on Larkin Hospital North as a second clinical trial site. We look forward to working with their research team as we advance our trial for using Zofin™ to treat moderate to severe acute respiratory syndrome due to COVID-19,” said Dr. Maria Ines Mitrani, Chief Science Officer of Organicell.
https://sec.report/Document/0001683168-20-004003/
Recent ZEOX News
- Form 8-K - Current report • Edgar (US Regulatory) • 09/20/2024 08:15:24 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 09/16/2024 08:15:28 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/07/2024 08:49:46 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 06/14/2024 08:15:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/03/2024 08:05:15 PM
North Bay Resources Commences Operations at Bishop Gold Mill, Inyo County, California; Engages Sabean Group Management Consulting • NBRI • Sep 25, 2024 9:15 AM
CEO David B. Dorwart Anticipates a Bright Future at Good Gaming Inc. Through His Most Recent Shareholder Update • GMER • Sep 25, 2024 8:30 AM
Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • BLOZF • Sep 24, 2024 8:50 AM
Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • INTV • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM